
Adjuvanted leptospiral vaccines: challenges and future development of new leptospirosis vaccines
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | (LDV) Lab. Desenvolvimento de Vacinas | pt_BR |
dc.contributor.author | Teixeira, Aline Rodrigues Florêncio | pt_BR |
dc.contributor.author | Fernandes, Luis Guilherme Vírgílio | pt_BR |
dc.contributor.author | Pereira, Maria Fernanda Cavenague | pt_BR |
dc.contributor.author | Takahashi, Maria Beatriz | pt_BR |
dc.contributor.author | Santos, Jademilson Celestino dos | pt_BR |
dc.contributor.author | Passalia, Felipe José | pt_BR |
dc.contributor.author | Daroz, Brenda | pt_BR |
dc.contributor.author | Kochi, Leandro Toshio | pt_BR |
dc.contributor.author | Vieira, Mônica Larucci | pt_BR |
dc.contributor.author | Nascimento, Ana Lúcia Tabet Oller do | pt_BR |
dc.date.accessioned | 2020-07-09T21:26:08Z | - |
dc.date.available | 2020-07-09T21:26:08Z | - |
dc.date.issued | 2019 | pt_BR |
dc.identifier.citation | Teixeira ARF, Fernandes LGV, Pereira MFC, Takahashi MB, Santos JC, Passalia FJ, et al. Adjuvanted leptospiral vaccines: challenges and future development of new leptospirosis vaccines. Vaccine. 2019 Jul;37(30):3961-3973. doi:10.1016/j.vaccine.2019.05.087. | pt_BR |
dc.identifier.uri | https://repositorio.butantan.gov.br/handle/butantan/2913 | - |
dc.description.abstract | Leptospirosis is a neglected infectious disease of global importance. Vaccination is the most viable strategy for the control of leptospirosis, but in spite of efforts for the development of an effective vaccine against the disease, few advances have been made, and to date, bacterin is the only option for prevention of leptospirosis. Bacterins are formulations based on inactivated leptospires that present a series of drawbacks, such as serovar-dependence and short-term immunity. Therefore, bacterins are not widely used in humans, and only Cuba, France and China have these vaccines licensed for at-risk populations. The development of recombinant DNA technology emerges as an alternative to solve the problem. Recombinant protein-based vaccines or DNA vaccines seem to be an attractive strategy, but the use of adjuvants is critical for achievement of a protective immune response. Adjuvants are capable of enhancing and/or modulating immune responses by exposing antigens to antigen-presenting cells. In the last years, several components have been tested as adjuvants, such as aluminum salts, oil based-emulsion adjuvants, bacteria-derived components and liposomes. This review highlights the use of adjuvants in the multiple vaccine approaches that have been used for leptospirosis and their most important immunological aspects. Immune response data generated by these strategies can contribute to the understanding of the immune mechanisms involved in protection against leptospirosis, and consequently, the development of effective vaccines against this disease. This is the first review on leptospiral vaccines focusing on adjuvant aspects. | pt_BR |
dc.description.sponsorship | (FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo | pt_BR |
dc.description.sponsorship | (CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico | pt_BR |
dc.description.sponsorship | (CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior | pt_BR |
dc.format.extent | 3961-3973 | pt_BR |
dc.language.iso | English | pt_BR |
dc.relation.ispartof | Vaccine | pt_BR |
dc.rights | Restricted access | pt_BR |
dc.title | Adjuvanted leptospiral vaccines: challenges and future development of new leptospirosis vaccines | pt_BR |
dc.type | Article | pt_BR |
dc.identifier.doi | 10.1016/j.vaccine.2019.05.087 | pt_BR |
dc.identifier.url | https://doi.org/10.1016/j.vaccine.2019.05.087 | pt_BR |
dc.contributor.external | (USP) Universidade de São Paulo | pt_BR |
dc.identifier.citationvolume | 37 | pt_BR |
dc.identifier.citationissue | 30 | pt_BR |
dc.subject.keyword | Leptospira | pt_BR |
dc.subject.keyword | Leptospirosis | pt_BR |
dc.subject.keyword | vaccine | pt_BR |
dc.subject.keyword | adjuvant | pt_BR |
dc.relation.ispartofabbreviated | Vaccine | pt_BR |
dc.identifier.citationabnt | v. 37, 30, p. 3961-3973, jul. 2019 | pt_BR |
dc.identifier.citationvancouver | 2019 July;37(30):3961-3973 | pt_BR |
dc.contributor.butantan | Fernandes, Luis Guilherme Virgílio|:Aluno|:(LDV) Lab. Desenvolvimento de Vacinas|: | pt_BR |
dc.contributor.butantan | Cavenague, Maria Fernanda|:Aluno|:(LDV) Lab. Desenvolvimento de Vacinas|: | pt_BR |
dc.contributor.butantan | Takahashi, Maria Beatriz|:Aluno|:(LDV) Lab. Desenvolvimento de Vacinas|: | pt_BR |
dc.contributor.butantan | Santos, Jademilson Celestino dos|:Aluno|:(LDV) Lab. Desenvolvimento de Vacinas|: | pt_BR |
dc.contributor.butantan | Passalia, Felipe José|:Aluno|:(LDV) Lab. Desenvolvimento de Vacinas|: | pt_BR |
dc.contributor.butantan | Daroz, Brenda|:Aluno|:(LDV) Lab. Desenvolvimento de Vacinas|: | pt_BR |
dc.contributor.butantan | Kochi, Leandro Toshio|:Aluno|:(LDV) Lab. Desenvolvimento de Vacinas|: | pt_BR |
dc.contributor.butantan | Vieira, Mônica Larucci|:Aluno|:(LDV) Lab. Desenvolvimento de Vacinas|: | pt_BR |
dc.contributor.butantan | Nascimento, Ana Lúcia Tabet Oller do|:Pesquisador|:(LDV) Lab. Desenvolvimento de Vacinas|:Autor de correspondência | pt_BR |
dc.contributor.butantan | Teixeira, Aline Rodrigues Florêncio|:Aluno|:(LDV) Lab. Desenvolvimento de Vacinas|:PrimeiroAutor | pt_BR |
dc.sponsorship.butantan | (CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦301229/2017-1 | pt_BR |
dc.sponsorship.butantan | (CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦441449/2014-0 | pt_BR |
dc.sponsorship.butantan | (CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior¦¦001 | pt_BR |
dc.sponsorship.butantan | (FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦14/50981-0 | pt_BR |
dc.identifier.bvscc | BR78.1 | pt_BR |
dc.identifier.bvsdb | IBProd | pt_BR |
dc.description.dbindexed | Yes | pt_BR |
item.fulltext | Com Texto completo | - |
item.languageiso639-1 | English | - |
item.openairetype | Article | - |
item.grantfulltext | embargo_29990101 | - |
crisitem.author.dept | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.dept | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.dept | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.dept | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.dept | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.dept | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.dept | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.dept | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.dept | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.dept | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.author.orcid | 0000-0003-4851-0870 | - |
crisitem.journal.journalissn | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
crisitem.journal.journaleissn | #PLACEHOLDER_PARENT_METADATA_VALUE# | - |
Appears in Collections: | Artigos |
Files in This Item:
Existing users please Login
10.1016j.vaccine.2019.05.087.pdf
Size: 729.53 kB
Format: Adobe PDF
Embargoed until January 1, 2999 Request a copy
Size: 729.53 kB
Format: Adobe PDF
Embargoed until January 1, 2999 Request a copy
The access to the publications deposited in this repository respects the licenses from journals and publishers.